Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- KYMR
- Price
- 72.77
- Stock movement up
- +2.03 (2.87%)
- Company name
- Kymera Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 5.82B
- Ent value
- 5.86B
- Price/Sales
- 133.11
- Price/Book
- 6.15
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 7.81%
- 1 year return (CAGR)
- 66.52%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KYMR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 133.11 |
| Price to Book | 6.15 |
| EV to Sales | 134.09 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 80.00M |
| EPS (TTM) | -3.38 |
| FCF per share (TTM) | -2.64 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 43.73M |
| Gross profit (TTM) | -32.44M |
| Operating income (TTM) | -332.26M |
| Net income (TTM) | -295.12M |
| EPS (TTM) | -3.38 |
| EPS (1y forward) | -3.71 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -74.18% |
| Operating margin (TTM) | -759.73% |
| Profit margin (TTM) | -674.81% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 112.95M |
| Net receivables | 0.00 |
| Total current assets | 528.30M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 110.43M |
| Total assets | 1.10B |
| Accounts payable | 5.51M |
| Short/Current long term debt | 84.00M |
| Total current liabilities | 71.58M |
| Total liabilities | 155.79M |
| Shareholder's equity | 946.26M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -227.93M |
| Capital expenditures (TTM) | 2.28M |
| Free cash flow (TTM) | -230.21M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -31.19% |
| Return on Assets | -26.78% |
| Return on Invested Capital | -30.74% |
| Cash Return on Invested Capital | -23.98% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 69.83 |
| Daily high | 72.86 |
| Daily low | 69.44 |
| Daily Volume | 563K |
| All-time high | 94.30 |
| 1y analyst estimate | 115.64 |
| Beta | 2.29 |
| EPS (TTM) | -3.38 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 19 Feb 2026 |
Downside potential
Loading...
Downside potential data
| KYMR | S&P500 | |
| Current price drop from All-time high | -22.83% | -0.89% |
| Highest price drop | -76.03% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -46.90% | -2.49% |
| Avg time to new high | 322 days | 6 days |
| Max time to new high | 291 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
5.82B
Marketcap category
Mid-cap
Description
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Employees
225
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page